

Supplementary material:

Table 1: Flavonoids and selective COX-2 blocker having anticancer activities.

Flavonoids	Pubchem id	Organ or tissue type	References
Delphinidin	CID 128853	Skin cancer	[84, 85]
Quercetin	CID 5280343	Skin cancer	[86, 87]
Myricetin	CID 5281672	Skin cancer	[88-92]
Equol	CID 91469	Skin cancer, Prostate cancer, Breast Cancer	[93, 94]
Isorhamnetin	CID 5281654	Article I. Skin cancer, Colon cancer, Colorectal cancer	[95-97]
Quercetin-3-methyl ether	CID 5280681	Article II. Skin cancer, Breast cancer, Leukaemia	[98-100]
Kaempferol	CID 5280863	Skin cancer, Colon cancer	[101-103]
Eriodictyol	CID 440735	Skin cancer, Breast Cancer	[104, 105]
Luteolin	CID 5280445	Skin cancer, Lung cancer, Prostate cancer, Colon cancer.	[106-110]
5-deoxykaempferol	CID 5281611	Skin cancer	[111]
7,3',4'-Trihydroxyisoflavone	CID 5284648	Skin cancer	[72]
4',6,7-trihydroxyisoflavone	CID 5284649	Colon cancer	[112]
Celcoxib	CID 2662	Cyclooxygenase-2 inhibitor in cancer	[113, 114]

Table 2: Summary of FlexX docking results with COX-2 and ligands.

Flavonoids	Score	Match	Lipo	Ambig	Clash	Rot	ΔG KJ/mol	Ligand Efficiency
Celcoxib	-26.85	-21.15	-14.73	-7.33	6.77	4.2	-29	0.27
Isorhamnetin	-20.93	-22.32	-11.21	-8.56	8.76	7.0	-30	0.31
5-deoxykaempferol	-19.26	-15.65	-11.83	-5.77	4.40	4.2	-29	0.35
Equol	-21.94	-17.43	-12.88	-5.71	4.48	4.2	-27	0.36
4',6,7-trihydroxyisoflavone	-20.61	-17.03	-10.03	-6.17	3.89	4.2	-26	0.31
Eriodictyol	-24.63	-24.97	-11.21	-7.43	6.58	7.0	-23	0.26
Quercetin	-21.66	-24.06	-11.19	-6.85	8.05	7.0	-20	0.21
Myricetin	-21.59	-23.18	-12.27	-7.26	7.38	8.4	-19	0.20
7,3',4'-Trihydroxyisoflavone	-26.25	-23.85	-11.82	-6.92	6.75	4.2	-18	0.22
Quercetin-3-methyl ether	-24.88	-25.55	-10.48	-7.76	6.51	7.0	-16	0.16
Kaempferol	-20.92	-17.93	-13.00	-7.33	6.35	5.6	-15	0.17
Delphinidin	-18.41	-23.92	-11.55	-7.36	10.36	8.4	-15	0.16
Luteolin	-27.67	-26.93	-10.23	-7.25	5.75	5.6	-13	0.14

Table 3: Type of interactions and interacting amino acid residues of COX-2 protein with selected ligands, generated from ArgusLab.

Flavonoids	Binding Energy kcal/mol	H-Bonding	Hydrophobic Bonding			Pi-Cation
			Pi - Alkyl	Pi-Pi	Pi-Sigma	
Celcoxib	-9.35	Q ¹⁹² , R ¹²⁰ , L ⁵³¹ , S ⁵³⁰	V ⁵²³ , A ⁵²⁷ , L ³⁵² , F ¹⁹⁸	-	V ³⁴⁹ , Y ³⁴⁸	-
Isorhamnetin	-8.25	-	V ³⁴⁹ , L ³⁵² , V ⁵²³	-	S ³⁵³ , A ⁵²⁷ , V ⁵²³	-
5-deoxykaempferol	-9.14	-	V ⁵²³ , I ⁵¹⁷ , A ⁵¹⁶	Y ³⁵⁵	V ³⁴⁹	-
Equol	-9.92	Q ¹⁹² , F ⁵¹⁸	V ⁵²³ , V ³⁴⁹ , L ³⁵² , L ⁵³¹ , A ⁵²⁷	-	-	-
4',6,7-trihydroxyisoflavone	-9.89	S ⁵³⁰	V ⁵²³ , A ⁵²⁷ , L ³⁵² , L ⁵³¹	-	V ³⁴⁹	-
Eriodictyol	-9.50	F ⁵¹⁸ , R ¹²⁰	-	-	A ⁵²⁷ , V ³⁴⁹ , V ⁵²³	-
Quercetin	-8.94	R ⁵¹³ , R ¹²⁰ , Q ¹⁹²	V ⁵²³ , V ³⁴⁹ , L ³⁵²	-	V ⁵²³ , A ⁵²⁷	-
Myricetin	-8.91	R ¹²⁰	V ³⁴⁹ , V ⁵²³	-	A ⁵²⁷ , V ⁵²³	-
7,3',4'-Trihydroxyisoflavone	-9.86	-	A ⁵²⁷ , V ⁵²³ , L ⁵³¹ , L ³⁵²	-	S ³⁵³ , V ³⁴⁹	-
Quercetin-3-methyl ether	-8.26	H ⁹⁰ , S ⁵³⁰	A ⁵²⁷ , V ³⁴⁹ , L ³⁵²	-	V ³⁴⁹ , V ⁵²³	-
Kaempferol	-10.64	W ³⁸⁵ , S ⁵³⁰	V ³⁴⁹ , L ³⁵²	-	L ³⁵² , V ⁵²³ , A ⁵¹⁶	-
Delphinidin	-8.94	E ⁵²⁴	V ⁸⁹ , V ¹¹⁶ , I ¹¹²	Y ³⁵⁵	L ⁹³	R ¹²⁰
Luteolin	-10.72	S ⁵³⁰	A ⁵¹⁶ , L ³⁵² , V ³⁴⁹	-	V ⁵²³	-